|Daily Range||$20.88 - $21.00|
|52-Week Range||$20.36 - $24.54|
|Dividend (Yield)||$0.00 (3.2%)|
|Average Daily Volume||54,280|
|Current FY EPS||$0.55|
News & Commentary
The little-known biopharma Sunesis Pharmaceuticals is on the cusp of unblinding late-stage trial data for its flagship oncology drug vosaroxin. Leading into this seminal event, management sounds fairly confident of a positive result, but the market clearly has its doubts. Why?
Takeda, Eli Lilly, Immunomedics, and Pharmacyclics could loom large in health care headlines this Tuesday morning.
Lower research and development expenses help lower Orexigen's quarterly loss.
A number of factors are holding back obesity therapies, but this one glimmer of light has the potential to change that perception.
Arena Pharmaceuticals takes the stage to highlight Belviq, other lorcaserin indications, and its remaining pipeline. Do investors have a reason to be excited?
The JPMorgan Healthcare Conference kicks off and Pharmacyclics dishes new pricing and duration data on key drug Imbruvica.
Sucampo's 8-K filing with the SEC delivers a nice surprise to shareholders.
These are the 10 countries with the longest life expectancy. See what factors have allowed their citizens to live longer as well as how you might be able to benefit from their longevity.
With Takeda's recent setback, Big Pharma's diabetes cupboard is looking very bare.
An FDA panel gives the green light on the use of vedolizumab to treat patients with ulcerative colitis and Crohn’s disease who failed other treatments.